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Background: Salivary duct carcinoma (SDC) is a highly aggressive subtype of salivary gland cancers and there is no
established standard therapy for this disease. Thus, development of molecular markers for SDC will be important to
guide the diagnosis and therapy of this aggressive tumor.
Methods: We performed next-generation sequencing using the Ion Torrent AmpliSeq cancer panel, which explores
the mutational status of hotspot regions in 50 cancer-associated genes, and we analyzed copy number variations
(CNVs) of 21 genes by NanoString nCounter for 37 patients with SDC. Fluorescent in situ hybridization was also
conducted to confirm ERBB2 gene amplification. Clinical records and tumor histopathology of the patients were
retrospectively reviewed.
Results: Genetic alterations were detected in 29 of 37 (78.3%) tumors, including mutations in PIK3CA (N = 9,
24.3%), ERBB2 (N = 4, 10.8%), and EGFR (N = 4, 10.8%). To our knowledge, this is the first time that ERBB2
mutations have been reported in this tumor type. Both PIK3CA and ERBB2 mutation status were associated with
poor overall survival, but without statistical significance. ERBB2 amplification was strong and common in SDC
and almost all cases also exhibited EGFR and ERBB3 amplifications.
Conclusions: This study reports the largest and most comprehensive analysis of DNA aberrations in SDC. Our
results show that PIK3CA and/or ERBB2 alterations in the development of SDC might be a useful diagnostic tool
and could serve as a potential therapeutic target.
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Salivary gland cancers (SGC) are rare, accounting for
fewer than 5% of all cancers of the head and neck [1].
SGC present numerous morphologic, biologic, and clin-
ically diverse entities. Salivary duct carcinomas (SDC)
are a rare and aggressive subtype of SGC [2,3]. It bears a
pathologic resemblance to ductal carcinoma of the breast
and shares hormonal and molecular marker alterations
with breast cancer [4]. SDC mainly arises de novo in the
parotid gland and most patients are older than 50 years.
The recurrence rate is high and metastases occur in lymph* Correspondence: silk.ahn@samsung.com
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unless otherwise stated.nodes, lung, liver, and bone [5]. Despite surgical resection
and postoperative radiotherapy, SDC has an extremely
poor prognosis [2,4] and most patients with SDC die from
progressive disease within 3 years [2,6].
To date, several chemotherapeutic agents have been
tested but none have shown significant efficacy [7]. Al-
though there are limited prior molecular studies of SDC,
many of these studies have suggested that overexpres-
sion of epidermal growth factor receptor 2 (ERBB2, also
known as HER2) is a common event in this tumor type.
Expression of ERBB2 has been linked to early local dis-
ease recurrence, distant metastasis, and poor survival
[2,8]. In spite of the high incidence of ERBB2 gene ampli-
fication, as detected by fluorescence in situ hybridization
(FISH), there has been no meaningful or reproducible
response to ERBB2-targeted therapy [4,9]. Furthermore,
given the rarity of the disease, comprehensive analyses ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics
Total (N =48) Patient (N)
Age (Median/Range) 59.3 (39.3-81.6) years











Operation + RT 25
Radiation dose (Median/Range) 5400 cGy (4000-6300 cGy)
Operation + CCRT 14








Palliative chemotherapy 2 (CAP, XP)
Palliative radiotherapy 4
Treatment response
No evidence disease 23
Stable disease 1
Recur or Progression 19/5





RFS (Median) 29.1 months
OS (Median) 76.2 months
RT: Radiotherapy; CCRT: Concurrent chemo-radiotherapy; DP: Docetaxel/Cisplatin;
FP: 5FU/Cisplatin; CAP: Cyclophosphamide/Doxorubicin/Cisplatin; RFS:
Recurrence-free survival; OS: Overall survival.
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genetic alterations in SDC should provide new opportun-
ities for the development of therapeutics.
Significant improvements in sequencing technology
and computational methods have led to the develop-
ment of next-generation sequencing (NGS) platforms.
Several NGS platforms are available for sequencing either
targeted genomic regions or whole genomes/exomes to
analyze a variety of disease-associated changes such as
point mutations, insertions, deletions, and copy number
variations (CNVs) [10]. These broad NGS applications
have facilitated the discovery of novel genetic aberrations
in disease and NGS may be a useful tool for mutation
screening for diagnosis and discovery [11].
In the present study, we used an AmpliSeq cancer panel
and NanoString nCounter assay to determine cancer-
associated mutations and CNVs in 37 SDC patients.
CNVs of ERBB2 that were detected using NanoString
nCounter assay were confirmed using FISH.
Methods
Tumor specimen and DNA extraction
All procedures involving tumor specimen were reviewed
and approved by the Institutional Review Board (IRB) of
Samsung Medical Center (SMC). Patient records/infor-
mation was anonymized and de-identified prior to ana-
lysis. We retrospectively identified 48 patients who were
diagnosed with SDC at Samsung Medical Center from
January 1997 to April 2010. A total of 37 cases of SDC
had adequate tissue available for DNA isolation. Gen-
omic DNA was extracted from formalin-fixed paraffin-
embedded tissue (FFPE) using the QIAamp DNA FFPE
Tissue Kit (Qiagen). Purified DNA was quantitated using
NanoDrop (Invitrogen Life Technologies) and Qubit
(Invitrogen Life Technologies).
Next-generation sequencing
Ion Torrent Ion AmpliSeq Cancer Hotspot Panel v2
(Life Technologies) was used to sequence hotspot re-
gions in 50 frequently mutated tumor suppressor genes
and oncogenes. For multiplex PCR amplification, 10 ng
of DNA (quantified by Qubit™ Fluorometer) was used
and the custom Ion AmpliSeq panel was processed with
Ion AmpliSeq Library kit 2.0 according to the manufac-
turer’s instructions. The resulting amplicons were treated
with FuPa Reagent to partially digest the primers and
phosphorylate the amplicons. The amplicons were then li-
gated to the Ion Xpress™ Barcode Adapters (1–96 Kit) and
template preparation was performed with the Ion One-
Touch™ System using Ion OneTouch™ 200 Template Kit
v2 DL. Sequencing was performed on Ion 316 chips using
the Ion PGM™ 200 Sequencing Kit according to the
manufacturer’s instructions. The raw signal data were
analyzed using Torrent Suite v.4.0.2 (Life Technologies).The pipeline includes signaling processing, base calling,
quality score assignment, adapter trimming, read align-
ment (Torrent Mapping Alignment Pregram; TMAP) to
human genome (HG) 19 reference, mapping quality con-
trol, and coverage analysis. Variant calling was performed
using the Torrent variant Caller 4.0 software. COSMIC
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program.Copy number alteration analysis
For detection of CNVs in salivary ductal carcinoma, a
panel of customized gene probes was designed using
NanoString nCounter technology and subsequently ana-
lyzed on the NanoString nCounter platform. NanoString
probes were composed of the following 21 genes (in alpha-
betical order): AURKA, CCND1, CCNE1, CDK4, CDK6,
CDKN1A, CDKN2A, EGFR, ERBB2, ERBB3, FGFR1,
FGFR2, IGF1R, KLF5, KRAS, MDM2, MET, MITF,
MYC, PIK3CA, TNIK. For the nCounter assay, 600 ng
of genomic DNA was hybridized with the custom de-
signed code set for 18 hours at 65°C and processed
according to the manufacturer’s instruction. The data
were normalized to the invariant control probes and
to positive and negative controls in each hybridization
reaction.Figure 1 Heatmap of the mutations found in 37 SDC samples. In the u
and the third row age. (Left) the histogram shows the percentage of muta
dataset of patients and the vertical axis illustrates mutated genes.Fluorescence in situ hybridization
To evaluate copy number changes in the ERBB2/HER2
gene, a 4-μm section of FFPE tumor tissue was analyzed
by dual-color FISH using the PathVysion HER2 DNA
Prove Kit (Abbott Molecular), which includes HER2
Spectrum Orange and centromere 17 (CEP17) Spectrum
Green.Statistical analysis
Patient characteristics were compared using chi-square
and Fisher’s exact tests (categorical variables). Survival
time was estimated using the Kaplan-Meier method and
compared for statistical differences by log-rank analysis.
Multivariate analysis was performed using stepwise cox
proportional hazards regression modeling to assess the
independent prognostic role of each clinicopathologic
variable. Statistical analyses were performed using SPSS19.0
(SPSS Inc.) and statistical significance was considered
to be p <0.05.pper panel, the first row indicates sex, the second row cancer stage,
tions in each gene. (Right) The horizontal axis presents the complete
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Clinical characteristics of the cohort
Characteristics of all 48 patients are listed in Table 1.
The median age was 59.3 years (range 39.3-81.6 years)
and male patients were predominant (75%; 36/48). The
primary tumor site was the parotid gland in 38 (80%)
cases and the submandibular gland in 10 cases (20%).
Regarding tumor stage, the majority (44%) of patients
presented with stage IV disease. Surgery was performed
for 41 patients (85.4%) and postoperative radiotherapy
and/or chemotherapy were performed for 24 (50%) and
14 (29%) cases, respectively. Among patients who did
not undergo surgery, 1 case was treated with concurrent
chemo-radiotherapy, 2 cases with palliative chemother-
apy, and 4 cases with palliative radiotherapy. Among 42
patients who underwent surgery, 19 cases (45.2%) had
recurrence of disease at either locoregional or distant
sites and 23 cases (54.8%) showed no evidence of dis-
ease. With a median follow-up of 44.7 months (range:
3.7-214.0 months), the median recurrence-free survival
(RFS) time was 17.3 months (95% CI, 14.2-20.4) and me-
dian overall survival (OS) time was 76.2 months (95%
CI, 15.7-136.7). Among the 48 patients, only 37 cases of
SDC had adequate tissue available for DNA isolation.
Molecular profiling of SDC
To evaluate genetic abnormalities occurring in SDC, we
applied NGS technology using the Ion Torrent Ion
AmpliSeq Cancer Hotspot Panel. Among the detectedTable 2 Mutations found in 37 SDCs by AmpliSeq
Gene Accession Number of
mutations
M
APC NM_000038 8 G
ATM NM_000051 3 E
EGFR NM_005228 7 V
ERBB2 NM_004448 4 I7
ERBB4 NM_005235 5 A
FBXW7 NM_033632 3 G
HRAS NM_176795 2 G
KIT NM_000222 7 D
KRAS NM_004985 4 G
MET NM_000245 1 N
PIK3CA NM_006218 15 E
A
PTEN NM_000314 10 W
SMAD4 NM_005359 10 Q
STK11 NM_000455 4 Q
TP53 NM_001126112 33 A
V
V
Gmutations, only mutations annotated in the Catalogue of
Somatic Mutations in Cancer (COSMIC) database were
considered. Twenty-nine of 37 (78.3%) patients pos-
sessed more than one mutation in this analysis (Figure 1).
Genes with identified mutations included APC (8 muta-
tions), ATM (3), EGFR (7), ERBB2 (4), ERBB4 (5), FBXW7
(3), HRAS (2), KIT (7), KRAS (4), MET (1), PIK3CA (15),
PTEN (10), SMAD4 (10), STK11 (4), and TP53 (33)
(Table 2). With the exception of TP53 and KIT mutations,
the most frequently identified mutations were in PIK3CA
(15 mutations in 9 patients). Three hotspot mutations
(E542K, E545K, and H1047R) of PIK3CA were observed
in 13.5% of patients (5/37). Although seven EGFR muta-
tions were detected, there were no cases with activating
EGFR mutations (exon 19 deletion or L858R), which are
well-known gene abnormalities in non-small cell lung
cancer. Interestingly, in addition to ERBB2 amplification,
which is known to be a common event in SDC [4], our re-
sults also revealed ERBB2 mutations in four patients at
four different loci: I767M, D769Y, G776V, and V842I.
The KRAS mutations identified in this study were not
in codons G12, G13, or Q61, which impair the intrinsic
GTPase activity of RAS and sustain the activation of
RAS signaling [12].
The CNVs were also tested and validated by using Nano-
String nCounter technology. The results showed that 14 of
the 21 genes had CNV, including both copy number ampli-
fications and losses. These genes included CCND1 (83.7%),
CDK4 (91.8%), CDKN1A (100%), CDKN2A (35.1%), EGFRutations
1106R, A1347T, P1361L, E1374K, Q1378X, S1434N, G1466E, H1490Y
848K, D1693N, A1742V
765M, A859T, A864V, E865K, E866K, A871T, G874S
67M, D769Y, G776V, V842I
287T, S341L, D609N, R612Q, P619L
391D, D440N, R441W
13S, Q61R
496N, M541L, W557X, E561K, W582X, A636V, A637F
15S, T35I, E49K, E63K
375S
65K, R88X, R108H, E110K, S326F, V344M, D350N, E542K, E545K, D1018N,
1020T, E1037K, M1043I, H1047R, G1049D
111X, D115N, G132S, M134I, R233X, R234Q, Q245X, E256K, T319fs, P339L
116X, R135X, Q256X, P356S, P356L, R496H, R497H, C499Y, W509X, R531W
170X, G171S, P281L, F354L
78V, P80L, A86V, S95F, V97A, P98L, R110C, S127fs, P128fs, K132R, C135W,
157G, R181C, Q192X, H193Y, R213Q, S215R, P219S, P223S, G226D, S241F,
272G, R273C, A276D, D281N, R282W, E285K, E286G, E287K, R290H,
293R, G302E, E339K
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(86.4%), KRAS (100%), MET (64.8%), MITF (43.2%), MYC
(72.9%), and PIK3CA (45.9%) (Table 3). Of note, ERBB2
exhibited the highest prevalence of strong gene amplifica-
tion in SDC (Figure 2A). Using FISH, we confirmed ERBB2
gene amplification in 29 cases of SDC. Representative im-
ages of SDC cases exhibiting ERBB2 gene amplification are
illustrated in Figure 2B. As all patients in this cohort had
ERBB2 gene amplification (copy number >2), we classified
these patients into moderate (copy number <10) and
strong (copy number >10) amplification of ERBB2. When
survival was analyzed according to amplification status of
ERBB2, there was no difference in disease-free survival and
overall survival between the two groups (Figure 2C).
Impact of molecular marker status on clinical outcomes
Given the high incidence of PIK3CA or ERBB2 gene ab-
normalities in this cohort, we investigated the association
between molecular status and survival. Kaplan-Meier
survival curves were plotted according to PIK3CA or
ERBB2 mutation status (Figure 3). In the case of PIK3CA
(Figure 3A) or ERBB2 (Figure 3B) mutation, both disease-Table 3 The frequency CNV in 37 SDCs by NanoString
nCounter analysis








AURKA 37 0 (0) 4 (10.8) 4 (10.8)
CCND1 37 31 (83.7) 0 (0) 31 (83.7)
CCNE1 37 2 (5.4) 5 (13.5) 7 (18.9)
CDK4 37 34 (91.8) 0 (0) 34 (91.8)
CDK6 37 6 (16.2) 4 (10.8) 10 (27)
CDKN1A 37 37 (100) 0 (0) 37 (100)
CDKN2A 37 10 (27) 3 (8.1) 13 (35.1)
EGFR 37 30 (81) 0 (0) 30 (81)
ERBB2 37 37 (100) 0 (0)) 37 (100)
ERBB3 37 30 (81) 0 (0) 30 (81)
FGFR1 37 8 (21.6) 1 (2.7) 9 (24.3)
FGFR2 37 3 (8.1) 2 (5.4) 5 (13.5)
IGF1R 37 0 (0) 14 (37.8) 14 (37.8)
KLF5 37 32 (86.4) 0 (0) 32 (86.4)
KRAS 37 37 (100) 0 (0) 37 (100)
MDM2 37 5 (13.5) 2 (5.4) 7 (18.9)
MET 37 24 (64.8) 0 (0) 24 (64.8)
MITF 37 0 (0) 16 (43.2) 16 (43.2)
MYC 37 27 (72.9) 0 (0) 27 (72.9)
PIK3CA 37 3 (8.1) 14 (37.8) 17 (45.9)
TNIK 37 5 (13.5) 4 (10.8) 9 (24.3)
Copy number amplification: copy number >2.
Copy number loss: copy number <2.free survival (DFS) and overall survival (OS) curves
shifted down. Although there was a tendency toward
lower survival in patients with gene mutation (median
OS: 76.2 months for wild-type vs. 20.8 months for PIK3CA
mutation; 70.9 months for wild-type vs. 20.8 months for
ERBB2 mutation), the association was not statistically
significant.
Discussion
Salivary duct carcinoma is an aggressive subtype of saliv-
ary gland cancers with histologic similarities to ductal
breast carcinoma. Although patients can receive effective
therapy including surgical resection followed by radi-
ation therapy or chemotherapy, the high recurrence rate
results in poor prognosis [4,7]. The most active single
agents for SDC include cisplatin, cyclophosphamide,
doxorubicin, and 5-FU. Response rates for combination
chemotherapy are reported to be 15-50% [7]. Given the
lack of promising therapeutics in SDC, in this study we
aimed to investigate molecular features that can predict
responses to therapy and characterize molecular markers
for SDC by evaluating genetic status.
Consistent with previous studies, our patient popula-
tion consisted mostly of males (75%) older than 50 years,
who presented with advanced disease (stage IV: 44%). In
this cohort, we identified a number of mutations and
CNVs in several genes. Among these, oncogenic PIK3CA
showed a high incidence of mutations in SDC patients
(24.3%). The PI3K axis plays a critical role in tumorigen-
esis and the availability of small molecular inhibitors of
this pathway renders it an attractive therapeutic target
[13]. Recently, somatic mutations in PIK3CA have been
identified in a variety of human tumors. Most of the re-
ported mutations of PIK3CA are clustered in exons 9
and 20 of the gene [14,15], where three hotspot muta-
tions (E542K, E545K, and H1047R) reside. Two of these
hotspot mutations (E542K and E545K) are located in the
helical domain (exon 9) whereas H1047R is located in
the kinase domain (exon 20) of the PIK3CA protein. All
three hotspot mutations have been proven to be onco-
genic and are associated with poor clinical outcomes
[16-18]. In our study, five patients had hotspot muta-
tions in PI3KCA (one each with E542K and E545K, and
three with H1047R). These results are consistent with
recent studies that reported PIK3CA mutations in SDC
[19-21]. In addition to gain-of-function mutations, PIK3CA
is activated through gene amplifications in several cancers
[18,22,23]. However, the nCounter CNV assay revealed no
significant amplification of PIK3CA in SDC patients in this
study (Figure 2). In addition to PIK3CA alterations, the
phosphatase and tensin homolog (PTEN) also activates the
PI3K pathway, and PTEN deletion was recently reported in
SDC by FISH analysis [21,24]. We found 10 PTEN muta-
tions in 5 out of 37 cases of SDC. Because of the limited
Figure 2 (See legend on next page.)
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Figure 2 Copy number variations in SDC. A. Copy number variations of 37 SDC samples by the NanoSting nCounter Cancer Copy Number
Variation Panel. The horizontal axis represents the complete dataset of patients and the vertical axis indicates examined genes. B. ERBB2 gene
amplifications were confirmed by FISH analysis, showing clusters of red signals (ERBB2 probe) and 2 green probes (chromosome 17) per nucleus
(DAPI staining). C. Disease-free survival (left) and overall survival (right) depicted according to the ERBB2 gene amplification. Patients grouped by
strong (copy number ≥10) and moderate (copy number <10) amplification of ERBB2.
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these alterations of PIK3CA or PTEN are associated with
aberrant protein expression and subsequent activation of
the PI3K pathway. However, a previous study reported that
PIK3CA amplification appears to be exceedingly rare in
SDC, and that PIK3CA mutation may be seen simultan-
eously with PTEN loss [21]. Further study is required to as-
sess whether PIK3CA mutation could be the predictor of
poor prognosis in SDC.
In addition to the histologic resemblance, SDC is similar
to breast ductal carcinoma regarding overexpression of
ERBB2 and EGFR in many cases [25-30]. ERBB2 gene
amplification and protein overexpression occurs in 20-30%Figure 3 Kaplan-Meier curves for disease-free survival (DFS) and over
depicted according to the presence or absence of genetic abnormalities: A
revealed no significant differences but indicated a trend toward better survof breast cancers and is reported to be a significant pre-
dictor of poor prognosis [31]. Similarly, the majority of
cases of SDC appear to strongly overexpress ERBB2. Con-
sistent with previous studies, the majority of our cohort ex-
hibited strong (copy number ≥10) amplification of ERBB2.
The high concordance between immunohistochemistry
and FISH analyses suggests that gene amplification is
the most important mechanism for ERBB2 overexpression
in this tumor [25,28,32,33]. These findings all point to a
potential role for trastuzumab, an anti-ERBB2 antibody, in
the treatment of SDC. Several studies have reported clinical
results of treatment with trastuzumab in combination with
chemotherapy [9,30,34]. In these studies, selected SDC casesall survival (OS) analysis. Observed survival of SDC patients is
. mutations in PIK3CA and B. mutations in ERBB2. Statistical analysis
ival for patients without genetic mutation.
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mab. However, until now ERBB2 mutations had not been
identified in patients with SDC. It is therefore noteworthy
that we found ERBB2mutations in 4 of 37 patients. All these
mutations were in exons 17–19 (Table 2). Although the
functional relevance of these mutations has not been identi-
fied, patients with ERBB2 mutation had a shorter median
OS time than those without (20.8 vs. 70.9 months). This
finding suggests that in a subset of SDC patients, the pres-
ence of ERBB2 mutation represents a more attractive poten-
tial therapeutic target than ERBB2 amplification.
It has been reported that EGFR overexpression is a poor
prognostic factor in head and neck squamous cell carcin-
oma [35,36]. Moreover, cetuximab, an anti-EGFR mono-
clonal antibody, and/or gefitinib, an ATP-competitive
EGFR tyrosine kinase inhibitor (TKI), have been studied
in various types of salivary gland carcinoma [4,37-39], but
not in SDC. EGFR activation and downstream signaling
leads to increased cell proliferation and survival. Activat-
ing EGFR mutations are well described in non-small cell
lung cancer and have been reported in various cancers of
the salivary glands [25,39,40]. EGFR mutations are usually
localized within two hotspots in the kinase domains, spe-
cifically a deletion in exon 19 and an L858R point muta-
tion in exon 21. In addition, rare mutations have been
discovered elsewhere in the kinase domain, including
insertions in exon 20 [29]. In this study, we observed
7 EGFR mutations in 4 of 37 SDC patients. One of
these mutations (V765M) is in exon 20 and the others
(A859T, A864V, E865K, E866K, A871T, and G874S) are in
exon 21. Although those are not well-known hotspot mu-
tations, their close proximity to L858R suggests that they
may play a role in SDC progression.
Conclusions
In conclusion, we identified mutations in several genes
including PIK3CA, ERBB2, and EGFR and significant
gene amplification of ERBB2 in SDC. Given the small
number of cases in this study, the significance of specific
mutation types, mechanism of gene amplification, and
their relationship to other abnormalities has to be eluci-
dated in larger studies. In Kaplan-Meier analysis using
PIK3CA and ERBB2 genes, the presence of mutations
showed a higher correlation with overall survival than
copy number variation. Although the importance of
these mutations in SDC is still unchallenged, our results
suggest that further studies of these mutations may iden-
tify a new therapeutic candidate and aid development of
an effective treatment strategy in SDC.
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